Study published on new drug class targeting ACVR1 mutation for DIPG
Study published on new drug class targeting ACVR1 mutation for DIPG Scientists at The Institute of Cancer Research, London, along with colleagues at the Structural Genomics Consortium in Oxford, have published their findings on a new drug class that can kill brain cancer cells with mutations in the ACVR1 gene and shrink tumours in mice. Mutated versions [...]